Compare BWAY & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | OVID |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.5M | 503.9M |
| IPO Year | 2011 | 2017 |
| Metric | BWAY | OVID |
|---|---|---|
| Price | $10.25 | $2.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $19.27 | $6.40 |
| AVG Volume (30 Days) | 101.5K | ★ 2.4M |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $33.61 | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $10.21 | $1.18 |
| 52 Week High | $26.63 | $3.11 |
| Indicator | BWAY | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 50.37 |
| Support Level | N/A | $2.12 |
| Resistance Level | $12.12 | $2.67 |
| Average True Range (ATR) | 0.59 | 0.24 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 3.43 | 44.95 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.